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Lamotrigine (3,5-diamino-6-(2,3-dichlorphenyl)-1,2,4-triazine) is an antiepileptic drug 
effective in the treatment of bipolar disorder in a depressive phase (Calabrese et al. 1999; 
Goldsmith et al. 2003) and in prevention of relapse of bipolar depression (Calabrese et al, 
2003). Preclinical studies suggested that antidepressant effects of lamotrigine might be 
related to alterations of serotonin (5-hydroxytryptamine, 5-HT) neurotransmission 
(Consoni et al. 2006; Ahmad et al. 2005). Blood platelets might be used as a peripheral 
model for some processes (5-HT uptake, 5-HT2 receptors binding and monoamine 
oxidase activity) in the central 5-HT synaptosomes (Camacho and Dimsdale 2000). Since 
there are no data evaluating the effects of lamotrigine on platelet markers in patients, the 
aim of the study was to determine the effects of 6-weeks lamotrigine treatment on platelet 
5-HT concentration in patients with bipolar I disorder currently depressed (bipolar 
depression), and to compare the effect of lamotrigine with the effect of 6-weeks 
paroxetine treatment on platelet 5-HT concentration in patients with major depressive 
disorder (MDD).  
 
Both patients with bipolar depression and MDD were diagnosed by a structured clinical 
interview (First et al. 1995) for DSM-IV disorders (APA, 1994). In a nonrandomized 
prospective, open-label, comparative, 6-weeks study, 28 female patients 48.8 (SD 11.5) 
years old with bipolar depression were treated with lamotrigine (25-100 mg/day), and 51 
female patients with MDD 49.5 (SD 7.9) years old received paroxetine (20 mg/day). 
Lamotrigine was added to the current treatment in 14 patients: lithium (6 patients, 600-
900 mg/day; lithium plasma concentration 0.55-0.80 mmol/l); quetiapine (2 patients, 300-
400 mg/day), risperidone (3 patients, 2 mg/day), olanzapine (3 patients, 5-10 mg/day). 
All patients were allowed to take diazepam (up to 15 mg/day). Participants have signed 
informed consent, approved by the local Ethics Committee. They had ≥18 scores on the 
17- items Hamilton Depression Rating Scale (HAMD) (Hamilton 1960). Patients with 
bipolar depression additionally required less than 7 scores on Young Mania Rating Scale 
(Young 1978). The exclusion criteria were (a) substance abuse disorder within the 
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previous 6 months; (b) diagnosis of schizophrenia, schizoaffective disorder, dementia, 
posttraumatic stress disorder; (c) presence of psychotic features; (d) treatment with any 
medication known to influence platelet 5-HT concentration in previous 2-4 weeks; (f) 
duration of current depressive episode for more than 2 years, to exclude chronic 
depression; (g) for patients with BD a history of previous non-response to lamotrigine or 
lamotrigine-induced rash. Depressive symptoms (evaluated using HAMD) and platelet 5-
HT concentration (nmol/mg proteins), measured using spectrofluorimetric method (Muck-
Seler et al. 2002), were determined at baseline (a day before lamotrigine or paroxetine 
administration), and after 6 weeks of treatment. No symptoms of mania have emerged 
during lamotrigine treatment. Drop outs: 2 patients in lamotrigine group: one patient was 
lost during follow-up, and the other patient was excluded because of the rash, which was 
not visible on the examination, but the patient claimed she had a rash a day before; and 3 
patients in paroxetine were excluded since they complained of worsening of their 
depressive symptoms. No serious adverse events occurred during the study. Statistical 
evaluation of the results, expressed as means ± standard deviations (SD), was performed 
using repeated measures analysis of variance (RMANOVA) followed by Tukey’s test and 
multifactorial analysis of variance (MANOVA) with significance accepted when P<0.05.  
 
Patients with bipolar depression or MDD had significantly (P<0.001, RMANOVA) lower 
platelet 5-HT concentration after 6 weeks of lamotrigine or paroxetine treatment than at 
baseline (Table 1). MANOVA (df=3,141) revealed the significant main effects (F=46.01, 
P<0.001), significant effect of time (baseline vs. 6 weeks) of treatment (F=116.11, 
P<0.001), significant effects of drugs (lamotrigine vs. paroxetine; F=16.15, P<0.001) and 
significant interaction between time and drugs (F=5.48, P=0.021) on platelet 5-HT 
concentration. To further assess the inhibitory effect of lamotrigine on platelet 5-HT 
concentration in patients with bipolar depression, and to evaluate the possible effects of 
lamotrigine added to the current treatment with antipsychotic drugs or lithium on platelet 
5-HT concentration, patients with bipolar depression were subdivided into those treated 
with lamotrigine (only) and lamotrigine with antipsychotics, or lamotrigine without 
lithium, and lamotrigine with lithium. The results showed (Table 1) the significant 
(RMANOVA) decrease in platelet 5-HT values in both patients with bipolar depression 
taking lamotrigine only and in those taking lamotrigine with antipsychotic drugs or 
lithium. At baseline patients with bipolar depression (24.54 ± 2.67) and MDD (26.52 ± 
2.45) had similar total HAMD scores. The significant (RMANOVA) decreases in total 
HAMD scores were observed after treatment with lamotrigine (9.77 ± 7.54) in bipolar 
[F(1,25)=165.517, P<0.001], or paroxetine (11.98 ± 8.62) in MDD [F(1,47)=165.879, 
P<0.001] patients. 
 
To the best of our knowledge, this is the first report showing significantly lower platelet 
5-HT concentration in bipolar depressed patients treated for 6 weeks with lamotrigine in 
relatively low doses (up to 100 mg/day). Lower platelet 5-HT concentration might be 
associated with suicidal behaviour, previous treatment with selective serotonin reuptake 
inhibitors (SSRI), or female gender (see Muck-Seler et al., 1996; 2005). Since we 
included only female, non-suicidal patients matched for age, who were not previously 
treated with SSRI, platelet 5-HT concentration was not significantly affected by these 
variables. This inhibitory effect of lamotrigine on platelet 5-HT concentration persisted 
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when lamotrigine was added to the current antipsychotic or lithium treatment. Our results 
agree with in vitro data showing that lamotrigine inhibited 5-HT uptake in rat brain 
synaptosomes (Southam et al., 1998), and with the data from experimental animals, 
where lamotrigine reversed the chloroamphetamine-induced 5-HT syndrome in rats 
(Southam et al.1998), and reduced the immobility in an animal model of depression, 
suggesting that antidepressant effect of lamotrigine is mediated also by 5-HT 
mechanisms (Consoni et al. 2006). The antidepressant effect of lamotrigine in patients 
with bipolar depression was similar to the effect of paroxetine on platelet 5-HT 
concentration and on the HAMD scores in patients with MDD (Muck-Seler et al. 2002; 
2005), probably due to its inhibitory effect on 5-HT uptake in human platelets in vitro 
(Southam et al. 1998). The antidepressant effect of lamotrigine (present study) is in line 
with data showing that lamotrigine, as an augmentation therapy in depression, accelerated 
the onset of action of paroxetine (Normann et al. 2002) and fluoxetine (Barbosa et al. 
2003). In conclusion, lamotrigine, similarly to paroxetine in patients with MDD, 
decreased platelet 5-HT concentration in patients with bipolar depression. Our results 
suggest that lamotrigine possesses in vivo 5-HT uptake inhibiting property, and this 
effect might have contributed to its antidepressant activity.  
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Table 1. Platelet 5-HT concentration (mean ± SD) in female patients with bipolar 
depression (BD), before and after 6 weeks of lamotrigine treatment, in female patients 
with major depression (MDD), before or after 6 weeks of paroxetine treatment, and in 
patients with BD subdivided into groups with or without lithium or antipsychotic 
treatment. N is the number of subjects.  
 
 
Treatment 
 
N 
Platelet 5-HT 
concentration 
(nmol/mg proteins) 
Statistical analysis 
RMANOVA 
    F            df            P 
 
Patients with BD 
before lamotrigine 
  
 
26 
 
 
1.44  0.45 
after lamotrigine 26 0.93  0.34d 
Patients with MDD: 
before paroxetine 
 
48 
 
1.30  0.49 
after paroxetine 48 0.46  0.34e 
 
 
 
21.74       1,25       0.001 
 
 
141.35     1,47       0.001 
 
Patients with BD    
Lamotrigine only  
before treatment 
  
12 
 
1.59  0.47 
after treatment 12 1.03  0.46a 
Lamotrigine + antipsychotics 
before treatment 
 
14 
 
1.31  0.40 
after treatment 14 0.84  0.16c 
   
Lamotrigine without lithium  
before treatment 
  
20 
 
1.47 0.41 
after treatment 20 0.95  0.37f 
Lamotrigine with lithium 
before treatment 
 
6 
 
1.49  0.40            
after treatment 6 0.72  0.07b 
   
 
 
9.34        1,11      0.011 
 
 
12.16      1,13     0.004 
 
 
 
22.33       1,19    0.001 
 
 
18.59       1,5      0.008 
 
aP=0.011, bP=0.008,  cP=0.004, d,e,f P<0.001 vs. corresponding values before treatment 
(Tukey’s test)  
 
 
